Literature DB >> 26398430

VITRECTOMY FOR REFRACTORY MACULAR HOLE.

Ju Young Kim1, Oh Woong Kwon.   

Abstract

PURPOSE: To report two cases of the treatment of refractory macular hole.
METHODS: A retrospective case report of two patients who underwent vitrectomy for refractory macular hole.
RESULTS: Two patients underwent pars plana vitrectomy for refractory macular holes. However, the surgical methods differed in the two patients depending on whether the internal limiting membrane (ILM) remained or not. In the patient with the remnant ILM, pars plana vitrectomy, inversion of the remaining ILM flap, air-fluid exchange, and 5% C3F8 gas tamponade were performed. In the other case with no remaining ILM, pars plana vitrectomy, inversion and release of the margin of the macula hole, combined with autologous platelet concentrate, air-fluid exchange, and 5% C3F8 gas tamponade were performed. In both cases, good anatomical outcomes were achieved postoperatively.
CONCLUSION: Depending on whether the ILM remains or not, one of these two new surgical procedures can be selected. This protocol can yield positive surgical results.

Entities:  

Mesh:

Year:  2015        PMID: 26398430     DOI: 10.1097/ICB.0000000000000183

Source DB:  PubMed          Journal:  Retin Cases Brief Rep        ISSN: 1935-1089


  3 in total

1.  Comparing the inverted internal limiting membrane flap with autologous blood technique to internal limiting membrane insertion for the repair of refractory macular hole.

Authors:  Zhixiang Hu; Haishuang Lin; Qihua Liang; Ronghan Wu
Journal:  Int Ophthalmol       Date:  2019-08-28       Impact factor: 2.031

2.  Effects of mesenchymal stem cells and their exosomes on the healing of large and refractory macular holes.

Authors:  Xiaomin Zhang; Juping Liu; Bo Yu; Feifei Ma; Xinjun Ren; Xiaorong Li
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-08-30       Impact factor: 3.117

3.  Plasma Rich in Growth Factors in Macular Hole Surgery.

Authors:  Ronald M Sánchez-Ávila; Carlos A Robayo-Esper; Eva Villota-Deleu; Álvaro Fernández-Vega Sanz; Álvaro Fernández-Vega González; Borja de la Sen-Corcuera; Eduardo Anitua; Jesús Merayo-Lloves
Journal:  Clin Pract       Date:  2022-01-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.